Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiochemotherapy with capecitabine and oxaliplatin for unresectable pancreatic and biliary tract cancer (dose escalation)
2007-004814-15Phase 2Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Oct 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in pancreatic cancer (PC) and biliary cancer, sponsored by Policlinico Gemelli. Primary endpoint: Maximum tolerated dose of oxaliplatin. Started Oct 2007; status: terminated.
02
Drugs
oxaliplatin
03
Conditions
pancreatic cancer (PC)biliary cancer
Beyond the preview
Go deeper on 2007-004814-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004814-15.